These observations are likely to be of high relevance to the human disease, as shown in a trial for treatment of MS patients with an altered peptide ligand of MBP, which was terminated because of systemic hypersensitivity reactions to the peptide [24], [25]. The gene discussed is MBP; the disease is myeloid sarcoma.